Low‐dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. results of a multicenter randomized, double‐blind, placebo‐controlled trial

Arthritis & Rheumatism

Volumn 36, Issue 6, 1993, Pages 795-803

  Shiroky, Jeffrey B ^a,b,c,d   Neville, Carolyn ^a,b,c,d   Esdaile, John M ^a,b,c,d   Choquette, Denis ^a,b,c,d   Zummer, Michel ^a,b,c,d   Hazeltine, Mark ^a,b,c,d   Bykerk, Vivian ^a,b,c,d   Kanji, Mohamed ^a,b,c,d   St‐Pierre, Anne ^a,b,c,d   Robidoux, Lise ^a,b,c,d   Bourque, Lucienne ^a,b,c,d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c CREDIT VALLEY HOSPITAL   (Canada)

^d HÔPITAL CHARLES LEMOYNE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERHIDROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; VERTIGO;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGE; PLACEBOS; SUPPORT, NON-U.S. GOV'T;

EID: 0027285238     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780360609     Document Type: Article

References (25)

1. The comparative efficacy and toxicity of second‐line drugs in rheumatoid arthritis: results of two metaanalyses
2. Comparing second line drugs for RA: efficacy/toxicity tradeoffs (abstract)
3. Lowdose methotrexate treatment of rheumatoid arthritis: long‐term observations
4. Long‐term prospective trial of methotrexate in the treatment of rheumatoid arthritis: 84‐month update
5. Methotrexate therapy in rheumatoid arthritis: 2‐year retrospective followup study
6. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis
7. Serious liver disease in methotrexate‐treated rheumatoid arthritis patients (abstract)
8. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate
9. Liver histology in rheumatoid arthritis patients receiving long‐term methotrexate therapy
10. The pharmacology and clinical use of methotrexate
11. Leucovorin for methotrexate induced elevations in liver transaminases (abstract)
12. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
13. Therapeutic criteria in rheumatoid arthritis
14. A seven‐day variability study of 499 patients with peripheral rheumatoid arthritis
15. Measurement of patient outcome in arthritis
16. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates
17. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis
18. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis
19. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
20. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid
21. High dose intravenous methotrexate with leucovorin rescue in rheumatoid arthritis
22. High dose intravenous methotrexate for refractory rheumatoid arthritis
23. The effect of folic acid supplementation on the toxicity of low‐dose methotrexate in patients with rheumatoid arthritis
24. Prospective long term follow‐up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy, and radiological progression
25. Long‐term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months